MeSH term
Frequency | Condition_Probility | Animals | 11 | 0.0 |
Base Sequence | 4 | 0.0 |
Cell Division/drug effects | 3 | 0.0 |
DNA Primers | 3 | 0.0 |
Polymerase Chain Reaction | 3 | 0.0 |
Rats | 8 | 0.0 |
Research Support, Non-U.S. Gov't | 19 | 0.0 |
Combined Modality Therapy | 2 | 0.0 |
Female | 8 | 0.0 |
Humans | 32 | 0.0 |
Leukopenia/chemically induced | 2 | 11.0 |
Male | 9 | 0.0 |
Middle Aged | 6 | 0.0 |
Nausea/chemically induced | 4 | 13.0 |
Vomiting/chemically induced | 3 | 17.0 |
Antibiotics, Antineoplastic/*pharmacology | 5 | 4.0 |
Carubicin/*analogs & derivatives/pharmacology | 4 | 100.0 |
English Abstract | 9 | 0.0 |
Glioma/*pathology | 3 | 5.0 |
Tumor Cells, Cultured | 6 | 0.0 |
Drug Resistance, Multiple/*genetics | 2 | 3.0 |
Leukemia, T-Cell | 2 | 5.0 |
P-Glycoprotein/*genetics | 2 | 4.0 |
Cytarabine/administration & dosage | 2 | 2.0 |
Remission Induction | 2 | 0.0 |
Vincristine/administration & dosage | 2 | 1.0 |
Cell Survival/drug effects | 4 | 0.0 |
Clone Cells | 2 | 0.0 |
Comparative Study | 7 | 0.0 |
Dose-Response Relationship, Drug | 4 | 0.0 |
Kinetics | 3 | 0.0 |
Structure-Activity Relationship | 3 | 0.0 |
Adult | 2 | 0.0 |
Aged | 2 | 0.0 |
Anorexia/chemically induced | 2 | 28.0 |
Antibiotics, Antineoplastic/adverse effects/*therapeutic use | 2 | 25.0 |
Carubicin/adverse effects/*analogs & derivatives/therapeutic use | 2 | 100.0 |
Drug Administration Schedule | 2 | 0.0 |
Neoplasms/drug therapy/*metabolism | 2 | 11.0 |
Neutrophils/drug effects | 2 | 3.0 |
In Vitro | 3 | 0.0 |
Microscopy, Electron | 3 | 0.0 |
Injections, Intravenous | 2 | 0.0 |
*DNA Damage | 2 | 0.0 |
Cell Line | 7 | 0.0 |
Neoplasm Transplantation | 3 | 0.0 |
Rats, Wistar | 2 | 0.0 |
Evaluation Studies | 2 | 0.0 |
Biological Transport | 3 | 0.0 |
Cells, Cultured | 2 | 0.0 |
Mice | 3 | 0.0 |
Doxorubicin/metabolism | 2 | 33.0 |
Leukemia, Myeloid, Chronic | 2 | 8.0 |
Carubicin/*analogs & derivatives/metabolism/pharmacology | 2 | 100.0 |
*Drug Resistance | 2 | 4.0 |
Daunorubicin/*analogs & derivatives | 2 | 50.0 |
Antibiotics, Antineoplastic/*therapeutic use | 2 | 8.0 |
*Carubicin/*analogs & derivatives | 2 | 100.0 |
Transplantation, Heterologous | 2 | 0.0 |
Tumor Cells, Cultured/drug effects | 2 | 0.0 |
